Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated
Crossref DOI link: https://doi.org/10.1007/s40120-018-0114-z
Published Online: 2018-10-25
Published Print: 2018-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sohur, U. Shivraj
Gray, David L.
Duvvuri, Sridhar
Zhang, Yao
Thayer, Kathleen
Feng, Gang
Funding for this research was provided by:
Pfizer
Article History
Received: 5 July 2018
First Online: 25 October 2018